2. Search Result
Search Result
Results for "

Cytotoxic T lymphocytes

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

27

Peptides

16

Inhibitory Antibodies

4

Natural
Products

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113963
    Ac-​IETD-​CHO

    		Apoptosis Cancer
    Ac- IETD- CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac- IETD- CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac- IETD- CHO also inhibits cytotoxic T lymphocytes induced cell death .
    Ac-​IETD-​CHO
  • HY-142938
    RORγt agonist 3

    		ROR Inflammation/Immunology
    RORγt agonist 3 is a potent agonist of RORγt. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 3 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136326A1, compound 23) .
    RORγt agonist 3
  • HY-147008
    XP-524

    		Epigenetic Reader Domain Cancer
    XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .
    XP-524
  • HY-P990116
    Anti-Mouse osteopontin/SPP1 Antibody (103D6)

    		Osteopontin Inflammation/Immunology
    Anti-Mouse osteopontin/SPP1 Antibody (103D6) is a mouse-derived anti-mouse osteopontin/SPP1 IgG2c κ type antibody inhibitor. Anti-Mouse osteopontin/SPP1 Antibody (103D6) increases cytotoxic T lymphocyte lytic activity and suppresses colon tumor growth. Anti-Mouse osteopontin/SPP1 Antibody (103D6) ameliorates liver injury in common bile duct ligation (CBDL)-induced primary sclerosing cholangitis mice models .
    Anti-Mouse osteopontin/SPP1 Antibody (103D6)
  • HY-P5470
    LMP2A (426-434)

    		EBV IFNAR Inflammation/Immunology
    LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06 and A*02:07). LMP2A (426-434) can induce a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8 + IFN-γ + T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .
    LMP2A (426-434)
  • HY-P5742
    ELAAWCRWGFLLALLPPGIAG

    		EGFR Cancer
    ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .
    ELAAWCRWGFLLALLPPGIAG
  • HY-P5742A
    ELAAWCRWGFLLALLPPGIAG TFA

    		EGFR Cancer
    ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .
    ELAAWCRWGFLLALLPPGIAG TFA
  • HY-106374
    Elpamotide

    		VEGFR Cancer
    Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .
    Elpamotide
  • HY-P10838
    PL120131

    		PD-1/PD-L1 Apoptosis Inflammation/Immunology
    PL120131 is a PD-1/PD-L1 inhibitory peptide that can interfere with the interaction of PD-1/PD-L1 by binding to PD-1. PL120131 is capable of inhibiting the PD-1-mediated apoptotic signaling pathway, protecting Jurkat cells and primary lymphocytes from apoptosis. PL120131 aids in the antitumor activity of cytotoxic T lymphocytes (CTLs) .
    PL120131
  • HY-142937
    RORγt agonist 2

    		ROR Inflammation/Immunology
    RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17) .
    RORγt agonist 2
  • HY-P2495
    OVA (241-270)

    		Biochemical Assay Reagents Cancer
    OVA (241-270), a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .
    OVA (241-270)
  • HY-P2495A
    OVA (241-270) TFA

    		Biochemical Assay Reagents Inflammation/Immunology
    OVA (241-270) TFA, a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .
    OVA (241-270) TFA
  • HY-P9901
    Ipilimumab
    4 Publications Verification

    MDX-010; BMS-734016

    		 CTLA-4 Cancer
    Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
    Ipilimumab
  • HY-P990041
    Firastotug

    ADG-116

    		 CTLA-4 Inflammation/Immunology Cancer
    Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .
    Firastotug
  • HY-P9918
    Tremelimumab

    Ticilimumab; CP-675206

    		 CTLA-4 Inflammation/Immunology Cancer
    Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
    Tremelimumab
  • HY-P99760
    Nurulimab

    BCD-145

    		 CTLA-4 Cancer
    Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
    Nurulimab
  • HY-153209
    Adjuvant-4

    		Biochemical Assay Reagents Others
    Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.
    Adjuvant-4
  • HY-P99484
    Botensilimab

    AGEN 1181

    		 CTLA-4 Cancer
    Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
    Botensilimab
  • HY-P991139
    Futermestotug

    		CTLA-4 Cancer
    Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
    Futermestotug
  • HY-P3333
    KSPWFTTL

    		MHC Inflammation/Immunology Cancer
    KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .
    KSPWFTTL
  • HY-P3333A
    KSPWFTTL TFA

    		MHC Inflammation/Immunology Cancer
    KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .
    KSPWFTTL TFA
  • HY-P1569
    LCMV gp33-41
    2 Publications Verification

    		 Arenavirus Inflammation/Immunology
    LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .
    LCMV gp33-41
  • HY-P1569A
    LCMV gp33-41 TFA
    2 Publications Verification

    		 Arenavirus Inflammation/Immunology
    LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .
    LCMV gp33-41 TFA
  • HY-160768
    OTUB2-IN-1

    		Deubiquitinase Inflammation/Immunology Cancer
    OTUB2-IN-1, a specific inhibitor of OTUB2 (KD: ~12 μM), reduces PD-L1 protein expression in tumor cells and inhibits tumor growth by promoting robust intra-tumor infiltration of cytotoxic T lymphocytes (CTL) .
    OTUB2-IN-1
  • HY-P991530
    YH004

    		Biochemical Assay Reagents Inflammation/Immunology Cancer
    YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
    YH004
  • HY-153209G
    Adjuvant-4 (GMP)

    		Biochemical Assay Reagents Others
    Adjuvant-4 (GMP) is a GMP grade Adjuvant-4. Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.
    Adjuvant-4 (GMP)
  • HY-P2521
    NS2 (114-121), Influenza

    		Influenza Virus Infection Inflammation/Immunology
    NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructural protein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 + cytotoxic T lymphocyte (CTL) in antiviral immune responses .
    NS2 (114-121), Influenza
  • HY-P1835
    CEF8, Influenza Virus NP (383-391)

    		Influenza Virus Inflammation/Immunology
    CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B *2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity .
    CEF8, Influenza Virus NP (383-391)
  • HY-P10245
    Fusion glycoprotein (92-106)

    		RSV Inflammation/Immunology
    Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratory syncytial virus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .
    Fusion glycoprotein (92-106)
  • HY-P99027
    Ieramilimab

    LAG525; IMP701; Hu5A8

    		 LAG-3 Cancer
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
    Ieramilimab
  • HY-174713
    Human FASLG mRNA

    		mRNA Inflammation/Immunology
    Human FASLG mRNA encodes the human Fas ligand (FASLG) protein, a member of the tumor necrosis factor superfamily. The primary function of the FASLG is the induction of apoptosis triggered by binding to FAS. The FAS/FASLG signaling pathway is essential for immune system regulation, including activation-induced cell death (AICD) of T cells and cytotoxic T lymphocyte induced cell death. It has also been implicated in the progression of several cancers.
    Human FASLG mRNA
  • HY-P1862
    HSV-gB2 (498-505)

    		HSV Infection
    HSV-gB2 (498-505) is an immunodominant epitope from herpes simplex virus (HSV) glycoprotein B residues 498-505, acts as H-2Kb-restricted and HSV-1/2-cross-reactive cytotoxic T-lymphocyte (CTL) recognition epitope .
    HSV-gB2 (498-505)
  • HY-W009245
    Bz-RS-iSer(3-Ph)-OMe

    		HIV Infection Cancer
    Bz-RS-iSer(3-Ph)-OMe (compound 2), a Taxol derivative, inhibits HSV replication cycle at low cytotoxicity, blocks mitotic divisions of Vero cells, influences M-MSV induced tumor size and affects immune response by inhibiting PHA-induced T lymphocyte proliferation .
    Bz-RS-iSer(3-Ph)-OMe
  • HY-P10593
    Influenza A NP (383-391) (HLA-B27)

    		Transmembrane Glycoprotein Influenza Virus Cancer
    Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
    Influenza A NP (383-391) (HLA-B27)
  • HY-P9948
    Alemtuzumab

    Campath-IH

    		 Apoptosis Cancer
    Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
    Alemtuzumab
  • HY-163028
    ML-T7

    		Tim3 Cancer
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
    ML-T7
  • HY-P1855
    HER2/neu (654-662) GP2

    		EGFR Cancer
    HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .
    HER2/neu (654-662) GP2
  • HY-156871
    CAMK1D-IN-1

    		CaMK Cancer
    CAMK1D-IN-1 (compound I) is an inhibitor of CAMK1D, targeting cytotoxic T lymphocyte (CTL)-resistant tumor cells. CAMK1D impairs CTL-induced death receptor signaling and apoptosis by inhibiting caspases, making it a key and effective target for PD-L1-refractory tumors .
    CAMK1D-IN-1
  • HY-P10607
    IALYLQQNW

    		EBV Cancer
    IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .
    IALYLQQNW
  • HY-P1881
    HPV16-E711-20 epitope

    		HPV Cancer
    HPV16-E711-20 epitope is a well-known HLA-A *0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .
    HPV16-E711-20 epitope
  • HY-P990280
    Anti-Mouse CD27 Antibody (RM27-3E5)

    		TNF Receptor Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Anti-Mouse CD27 Antibody (RM27-3E5) is an agonistic rat-derived IgG2a κ type antibody, targeting to mouse CD27. Anti-Mouse CD27 Antibody (RM27-3E5) stimulates CD 27. Anti-Mouse CD27 Antibody (RM27-3E5) can be used for the researches of cancer and immunology, such as B16cOVA tumor .
    Anti-Mouse CD27 Antibody (RM27-3E5)
  • HY-N0591
    Dehydrocostus Lactone
    1 Publications Verification

    (-)-Dehydrocostus lactone; Epiligulyl oxide

    		 Bacterial Apoptosis p38 MAPK NF-κB MAPKAPK2 (MK2) Akt NO Synthase Interleukin Related Caspase Infection Inflammation/Immunology Cancer
    Dehydrocostus Lactone ((-)-Dehydrocostus lactone) is a natural sesquiterpene that can be isolated from Saussurea lappa. Dehydrocostus Lactone has multiple activities such as anti-inflammatory, antibacterial, anti-tumor, and immunomodulatory effects. Dehydrocostus Lactone has an MIC of 2 µg/mL against Mycobacterium tuberculosis. Dehydrocostus Lactone can also inhibit the killing activity of cytotoxic T lymphocytes and induce apoptosis in tumor cells .
    Dehydrocostus Lactone
  • HY-P990303
    Anti-Mouse 2C TCR Antibody (1B2)

    		Nuclear Factor of activated T Cells (NFAT) Others
    Anti-Mouse 2C TCR Antibody (1B2) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse 2C TCR. Anti-Mouse 2C TCR Antibody (1B2) recognizes determinants on the variable regions of both the α and β subunits of the TCR (T cell receptor) expressed by the mouse cytotoxic T lymphocyte clone 2C. Anti-Mouse 2C TCR Antibody (1B2) can be used for the detections of immunofluorescence and flow cytometry .
    Anti-Mouse 2C TCR Antibody (1B2)
  • HY-P99762
    Obrindatamab
    1 Publications Verification

    MGD009

    		 CD3 Cancer
    Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
    Obrindatamab
  • HY-P991354
    GR-1405

    		PD-1/PD-L1 Cancer
    GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .
    GR-1405
  • HY-175604
    SCL-1

    		PD-1/PD-L1 Cancer
    SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor. SCL-1 can inhibit PD-1/PD-L1 binding. SCL-1 increases T cells, B cells and natural killer cells. SCL-1 exerts strong tumor growth inhibitory effects that were mediated by effector T-cell induction inside tumors and the up-regulated expression of long non-coding RNAs as neoantigens leading to cytotoxic T lymphocyte activation. SCL-1 can be used for the research of cancer, such as triple-negative breast cancer .
    SCL-1
  • HY-P1920
    CEF19, Epstein-Barr Virus latent NA-3A (458-466)

    		EBV Inflammation/Immunology
    CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .
    CEF19, Epstein-Barr Virus latent NA-3A (458-466)
  • HY-N0591R
    Dehydrocostus Lactone (Standard)

    (-)-Dehydrocostus lactone (Standard); Epiligulyl oxide (Standard)

    		 Reference Standards Bacterial Apoptosis p38 MAPK NF-κB MAPKAPK2 (MK2) Akt NO Synthase Interleukin Related Caspase Infection Inflammation/Immunology Cancer
    Dehydrocostus Lactone (Standard) ((-)-Dehydrocostus lactone (Standard)) is the analytical standard of Dehydrocostus Lactone (HY-N0591). This product is intended for research and analytical applications. Dehydrocostus Lactone is a natural sesquiterpene that can be isolated from Saussurea lappa. Dehydrocostus Lactone has multiple activities such as anti-inflammatory, antibacterial, anti-tumor, and immunomodulatory effects. Dehydrocostus Lactone has an MIC of 2 µg/mL against Mycobacterium tuberculosis. Dehydrocostus Lactone can also inhibit the killing activity of cytotoxic T lymphocytes and induce apoptosis in tumor cells.
    Dehydrocostus Lactone (Standard)
  • HY-P3070
    H2-D b restricted epitopes VSV Nucleoprotein (52-59)

    		MHC Infection Others
    H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .
    H2-D b restricted epitopes VSV Nucleoprotein (52-59)
  • HY-P990848
    Anti-CTLA-4/CD152 Antibody (BN13)

    		CTLA-4 Infection Inflammation/Immunology
    Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human CTLA-4/CD152. Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. Anti-CTLA-4/CD152 Antibody (BN13) can be used for the researches of infection and immunology, such as human immunodeficiency virus (HIV) .
    Anti-CTLA-4/CD152 Antibody (BN13)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: